Pharmacovigilance – Products

Glucagon-like peptide-1 (GLP-1) analogs regulate systemic homeostasis, making them effective in the treatment of type 2 diabetes. However, their low bioavailability limits their detection and quantitation in biological matrices, causing challenges in drug development.

This article presents current techniques in oligonucleotide production and characterization, highlighting recent advancements that enhance the efficiency of these methods

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations.

This article explores how scientists are tackling the challenges and intensifying efforts to develop mRNA therapeutics for different diseases.

SOLASCURE Ltd, a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and which aims to accelerate wound debridement and contribute to wound bed preparation & healing.

PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822.

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.